Key Highlights
- LSE:FAB surged 19.05% on 28 August 2026, closing at 12.50p.
- The stock opened at 10.50p, reached an intraday high of approximately 13.50p and traded as low as 10.50p.
- Approximately 2.26 million shares traded, substantially above the company's recent average volume.
- Fusion Antibodies has recently received Australian Patent acceptance for technology covering antibody libraries and methods for designing them.
- The company is continuing to develop its proprietary OptiMAL® mammalian antibody library, designed to generate fully human antibodies.
- Additional OptiMAL® patent applications are progressing in Europe and China.
- FY2026 Revenue increased approximately 9% to £2.13 million, while gross Margin improved dramatically to 50% from 22%.
- Cash increased to approximately £1.04 million at 31 March 2026, compared with £0.40 million a year earlier.
- The company is developing a DR5 humanised therapeutic antibody programme targeting treatment-resistant cancers through a grant-supported project with Queen's University Belfast.
- Fusion Antibodies is also pursuing strategic partnerships and commercial projects with pharmaceutical, biotechnology and diagnostics customers.
- The key question for investors is whether the company's technology platforms can translate into larger commercial contracts, licensing opportunities and recurring revenue.
Fusion Antibodies LSE:FAB Shares Jump 19.05% on 28 August 2026
Fusion Antibodies plc emerged as one of the strongest-performing small-cap healthcare stocks on 28 August 2026, with LSE:FAB rising 19.05% to 12.50p.
The move was accompanied by unusually high trading activity. Around 2.26 million shares changed hands, compared with a recent average Volume of roughly 436,000 shares. The shares opened at 10.50p and moved as high as approximately 13.50p during the session.
The size of the move is particularly noteworthy because Fusion Antibodies remains a micro-cap business, with a Market Capitalisation of only around £15.6 million at the 28 August closing price.
For a company of this size, relatively modest changes in investor Demand can generate very large percentage movements.
However, the latest rally is also occurring against a backdrop of several important technology, intellectual-property and commercial developments.
The market is increasingly assessing whether Fusion Antibodies can evolve from a specialist contract research organisation into a company with proprietary technology platforms capable of generating higher-value recurring and licensing revenues.
Why Fusion Antibodies Is in Focus
Fusion Antibodies operates in the antibody discovery and development market.
The company provides services covering antibody discovery, engineering, characterisation, optimisation and production for pharmaceutical, biotechnology, diagnostic and research customers. Its capabilities extend across early-stage antibody development and pre-clinical programmes.
That creates an interesting Business model.
On one side, Fusion Antibodies can generate revenue from customer projects.
On the other, the company is developing proprietary technologies that could potentially create substantially larger opportunities through licensing, partnerships and commercial platform adoption.
The second component is particularly important for the Investment case.
OptiMAL® Is Becoming a Major Strategic Asset
The company's OptiMAL® platform is one of the most important developments investors are watching.
OptiMAL® is a mammalian antibody library designed to produce fully human antibodies for discovery and pre-clinical optimisation. The company says the platform is intended to streamline antibody discovery and reduce the need for subsequent humanisation or platform switching.
This could potentially provide customers with a faster pathway from target identification to an optimised antibody candidate.
The commercial opportunity is significant because antibody therapeutics represent one of the largest and most important areas of modern drug development.
If OptiMAL® demonstrates strong performance in customer projects, Fusion Antibodies could potentially build a valuable technology Franchise around the platform.
Australian Patent Development Adds Intellectual-Property Strength
One of the most recent developments came in August 2026, when Fusion Antibodies announced that IP Australia had issued a notice of acceptance for its Australian patent application covering an antibody library and associated design methodology.
The application covers two antibody families and methods for designing antibody libraries. The company expects the patent, once granted, to complement its OptiMAL® technology offering across antibody discovery, affinity maturation and sequence optimisation.
This distinction is important.
A notice of acceptance indicates that the claims have been found patentable, but it is not itself the final grant of patent rights. The company expects further administrative steps before the Australian patent is formally granted.
Nevertheless, the development strengthens the intellectual-property story around OptiMAL®.
Fusion Antibodies is also progressing additional applications in other territories, including Europe and China.
Why Intellectual Property Matters for LSE:FAB
For a small biotechnology company, proprietary intellectual property can be considerably more valuable than simply increasing service revenue.
A contract research business generally earns fees for work performed for customers.
A proprietary technology platform can potentially be commercialised repeatedly across multiple customers.
That creates the possibility of greater scalability.
If Fusion Antibodies can demonstrate that OptiMAL® delivers commercially valuable antibodies more efficiently or with desirable characteristics, the platform could potentially attract larger pharmaceutical and biotechnology partnerships.
The value of the intellectual property would therefore depend on commercial adoption, not simply the number of patents granted.
That is an important distinction for investors.
Four OptiMAL® Proof-of-Concept Studies
Fusion Antibodies states that OptiMAL® is currently being used in four proof-of-concept studies.
These projects are important because they represent the bridge between technology development and commercial validation.
Investors should watch for updates demonstrating:
Antibody quality
Discovery speed
Affinity
Specificity
Developability
Customer satisfaction
Repeat projects
Commercial contracts
Potential licensing opportunities
Successful results could materially strengthen the OptiMAL® investment thesis.
However, proof-of-concept projects should not automatically be treated as commercial contracts.
The critical next step is converting successful demonstrations into paying customer programmes and potentially larger strategic partnerships.
Financial Performance Is Improving
Fusion Antibodies' FY2026 trading update provides another reason investors are paying attention.
Revenue increased approximately 9% to £2.13 million, compared with £1.96 million in FY2025. More importantly, reported gross margin increased to 50% from 22%, with underlying gross margin at approximately 43%.
That is a substantial improvement.
The improvement suggests the company's revenue mix and project Economics are becoming more attractive.
For a small company, gross-margin expansion can be particularly important because even modest increases in revenue can produce a disproportionately positive effect on Gross Profit if higher-margin activities become a larger part of the business.
This could become increasingly relevant if proprietary platform revenues begin contributing more significantly.
Cash Position Has Also Improved
Fusion Antibodies ended FY2026 with approximately £1.04 million of cash, compared with £0.40 million at the end of FY2025.
The improvement provides some additional financial flexibility.
However, investors should recognise that £1.04 million remains relatively modest for a biotechnology company pursuing platform development, intellectual-property protection and customer projects.
Cash management will therefore remain important.
The company must balance investment in technology development against the need to reach a sustainable commercial revenue base.
The DR5 Cancer Programme Adds Major Optionality
Another important area investors should watch is Fusion Antibodies' DR5 therapeutic antibody programme.
The project is being developed with Queen's University Belfast through a grant-supported programme designed to develop a humanised antibody targeting the DR5 protein on cancer cells.
The objective is to develop a potentially clinic-ready therapeutic asset that could ultimately be licensed to a pharmaceutical or biotechnology company.
This is a potentially high-impact opportunity.
If successful, the project could create a completely different source of value from Fusion's service business.
However, therapeutic development is inherently high risk.
Moving from pre-clinical research to clinical development can take years and requires substantial funding.
The DR5 programme should therefore be viewed as long-term optionality rather than near-term guaranteed revenue.
Why Pharmaceutical Partnerships Matter
Fusion Antibodies has an established role supporting pharmaceutical and biotechnology companies with antibody development.
That customer exposure is strategically important because successful customer programmes can lead to repeat business.
The company has also highlighted new projects with global pharmaceutical companies and continued progress with strategic partnerships.
Repeat business is particularly valuable for a small contract research organisation.
It reduces dependence on constantly winning entirely new customers.
It can also increase customer lifetime value.
Investors should therefore watch whether Fusion Antibodies can convert initial projects into larger, multi-stage development programmes.
The Antibody Market Creates a Large Opportunity
Antibody therapeutics remain one of the most important areas of biotechnology.
Pharmaceutical companies continue investing heavily in Biologics because antibodies can be highly selective and can address a wide range of disease targets.
But antibody discovery is complex.
Drug developers need to identify candidates with the right combination of:
Binding affinity
Specificity
Stability
Safety
Manufacturability
Pharmacological characteristics
Fusion Antibodies' technology and services are designed to help customers address these challenges.
If the company can demonstrate that its platforms reduce development time or improve candidate quality, its commercial proposition could become increasingly attractive.
Why LSE:FAB Is a High-Risk, High-Reward Stock
The investment case has substantial upside potential, but the risks are equally significant.
Fusion Antibodies remains a very small company.
Its revenue base is only a few million pounds.
Its cash resources are limited.
Its proprietary platforms remain in relatively early stages of commercialisation.
And its therapeutic programmes involve significant scientific and regulatory uncertainty.
That means a single major contract or licensing agreement could have a material effect on the company's financial profile.
But the reverse is also true.
A delay in customer programmes, weak project flow or higher development costs could place pressure on the shares.
The Importance of Commercialisation
The biggest issue investors should watch is the transition from technology validation to commercial scale.
Patents are valuable.
Proof-of-concept studies are encouraging.
Customer projects are important.
But the market will ultimately want evidence that these Assets produce meaningful revenue.
For OptiMAL®, the most important future milestone could therefore be a major commercial agreement.
A pharmaceutical Partnership involving platform licensing or a significant antibody-discovery programme could materially change investor expectations.
Similarly, successful development of the DR5 programme could create a potential licensing opportunity.
What Could Drive LSE:FAB Higher?
Several catalysts could potentially sustain the current investor interest.
Further patent grants would strengthen the intellectual-property portfolio.
Positive results from OptiMAL® proof-of-concept studies could increase confidence in the technology.
New pharmaceutical customer contracts could improve revenue visibility.
Expansion of strategic partnerships could provide additional commercial validation.
A licensing agreement involving OptiMAL® could be particularly significant.
Progress on the DR5 programme could also generate substantial interest if the project moves toward a clinic-ready asset.
Improving gross margins and stronger cash generation would provide an additional financial catalyst.
What Could Send the Stock Lower?
The principal downside risk is execution.
If OptiMAL® takes longer than expected to generate commercial revenues, investors may become less willing to value the company on future platform potential.
Customer project delays could affect revenue.
The company's small cash position also means funding remains an important consideration.
Additional fundraising could dilute existing shareholders if Operating Cash Flow does not improve sufficiently.
Therapeutic development carries further risks.
Even promising pre-clinical antibody candidates can Fail during later development.
Investors should therefore avoid treating the DR5 programme as a near-term certainty.
Why the 13.50p Intraday High Matters
LSE:FAB reached approximately 13.50p intraday on 28 August, substantially above its 10.50p opening price. The stock ultimately closed at 12.50p.
The move brought the shares further away from their recent 52-week low of around 9.50p and closer to the broader 52-week range, although the stock remained well below its 52-week high of roughly 20.50p to 21p.
This illustrates the substantial Volatility inherent in the shares.
The latest rally is therefore significant, but investors should not assume that a sharp one-day gain automatically establishes a new long-term trend.
The next fundamental announcements will be crucial.
Why Investors Should Watch September and November
The company's upcoming financial calendar provides additional potential catalysts.
The Annual Report and final results are expected around September 2026, while half-year results are expected in November 2026.
These updates could provide investors with a clearer picture of:
FY2026 audited financial results
Current-year trading
Customer project flow
Cash utilisation
OptiMAL® progress
Patent developments
Strategic partnerships
Commercial pipeline
Management's outlook
Given the company's small market capitalisation, even modest changes in expectations could have a disproportionate impact on the share price.
Fusion Antibodies' Potential Transformation
The most interesting aspect of LSE:FAB is that the company potentially has two complementary businesses.
The first is the existing antibody-services operation.
The second is the proprietary technology-platform opportunity.
If the service business continues producing revenue while OptiMAL® becomes commercially successful, Fusion Antibodies could potentially develop a more diversified revenue model.
That could include project-based services, platform revenues, licensing income and potentially future milestone payments.
Such a model could be considerably more valuable than a pure contract research business.
Investor Outlook for LSE:FAB
The 19.05% gain in LSE:FAB on 28 August 2026 has put Fusion Antibodies firmly back into focus among speculative UK healthcare investors.
The move was accompanied by approximately 2.26 million shares of trading volume, highlighting the scale of investor interest.
The fundamental story contains several attractive elements.
FY2026 revenue increased to £2.13 million.
Gross margin improved dramatically.
Cash strengthened.
The OptiMAL® platform is advancing.
Australian patent protection is progressing.
Additional intellectual-property applications are underway.
Four OptiMAL® proof-of-concept studies are in progress.
The DR5 cancer programme offers longer-term therapeutic optionality.
And the company continues to pursue pharmaceutical and biotechnology partnerships.
The key challenge is converting all of these developments into repeatable commercial revenue.
That is what investors should watch most closely.
If OptiMAL® demonstrates strong results and attracts major customers or licensing partners, the company could potentially experience a significant change in scale.
If customer projects continue growing while margins remain strong, the core business could provide an increasingly stable financial foundation.
But the company remains a micro-cap biotechnology investment with substantial execution and funding risks.
The latest rally therefore makes LSE:FAB a stock worth watching closely, but the next stage of the investment case will depend on evidence rather than speculation.
The most important milestones are likely to be OptiMAL® commercialisation, patent grants, pharmaceutical contracts, DR5 progress, cash generation and the company's upcoming financial results.
For investors willing to accept substantial volatility, Fusion Antibodies offers potentially significant upside if its proprietary technology platforms gain commercial traction.
For more conservative investors, the key requirement will be seeing stronger evidence that technology development is translating into sustainable revenue and cash generation.






Please wait processing your request...